The Utility of Platelet Rich Plasma in Hair Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03376581|
Recruitment Status : Active, not recruiting
First Posted : December 18, 2017
Last Update Posted : July 16, 2018
Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation.
The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.
|Condition or disease||Intervention/treatment||Phase|
|Androgenetic Alopecia||Procedure: Platelet rich plasma||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Utility of Platelet Rich Plasma in Hair Loss|
|Actual Study Start Date :||November 28, 2017|
|Estimated Primary Completion Date :||October 2018|
|Estimated Study Completion Date :||December 2018|
|Experimental: Prospective treatment||
Procedure: Platelet rich plasma
Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
- Hair density to measure the efficacy of treatment [ Time Frame: 6 months ]
- Hair count (number of hairs/0.65 cm2) [ Time Frame: 6 months ]
- Terminal hair density [ Time Frame: 6 months ]
- Anagen hair percentage [ Time Frame: 6 months ]
- Telogen hair percentage [ Time Frame: 6 months ]
- Anagen/telogen ratio [ Time Frame: After 3 and 6 months ]
- Changes in hair structure, diameter, and blood flow [ Time Frame: 6 months ]As measured by optical coherence tomography
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376581
|United States, California|
|University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Hewitt Hall|
|Irvine, California, United States, 92697|